The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Capricor Therapeutics and Nippon Shinyaku Partner for European Expansion of Deramiocel for Duchenne Muscular Dystrophy Treatment
Sep 17, 2024•almost 2 years ago
Contract Type
partnership
San DiegoBiotechnologyTherapeutics
Description
Capricor Therapeutics has signed a binding term sheet with Nippon Shinyaku for the European commercialization and distribution of deramiocel, a treatment for Duchenne muscular dystrophy. Nippon Shinyaku has agreed to invest $15 million in Capricor and an upfront payment of $20 million upon signing a definitive agreement, with the potential for additional milestones and a percentage of product revenue. The partnership extends Capricor's cash runway and opens doors for further global distribution.
Company Information
Company
Capricor Therapeutics
Location
San Diego, California, United States
About
Capricor Therapeutics is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases.
San DiegoBiotechnologyTherapeutics